Oral magnesium supplementation decreases alanine aminotransferase levels in obese women
Oral magnesium supplementation decreases alanine aminotransferase levels in obese women
复制标题
DOI：
10.1684/mrh.2010.0204
复制
发表时间：
2010-06-01
影响因子：
3.2
通讯作者：
Guerrero-Romero, Fernando
中科院分区：
文献类型：
--
作者：
Rodriguez-Hernandez, Heriberto;Cervantes-Huerta, Miriam;Guerrero-Romero, Fernando
为了评价口服补充氯化镁对全身和肝脏炎症的影响，将38名年龄在30至65岁的非高血压肥胖女性分为低镁血症组和非低镁血症组。低镁血症女性饮用50 mL 5% MgCl 2溶液，相当于450 mg元素镁。低碳水化合物饮食和体力活动是指两组妇女。排除标准为慢性腹泻、饮酒、使用利尿剂、既往口服镁补充剂、肝病和肾损害。低镁血症定义为血清镁浓度≥ 40 U/L，全身性炎症定义为血清高敏C反应蛋白（hs-CRP）浓度≥ 3 mg/L。在基线（p = 0.06）和最终随访（p = 0.80）时，研究中各组之间的体重指数无显著差异。同样，在基线时，补充和未补充的女性中ALT（48.1 +/- 25.5和34.6 +/- 24.1 U/L，p = 0.14）和hs-CRP（9.4 +/- 6.0和7.9 +/- 5.9 mg/dL，p = 0.47）水平相似。在镁组中，ALT（24.3 +/- 10.3和34.8 +/- 13.6 U/L，p = 0.02）水平，但不是hs-CRP（5.2 +/- 1.9和8.0 +/- 5.6 mg/L，p = 0.08）在治疗的第四个月达到显著低于对照组的水平。血清镁改善与ALT和hs-CRP水平降低之间的校正比值比分别为0.56（95%CI：0.3-0.9）和0.93（95%CI：0.6-29.9）。这项研究的结果表明，在低镁血症的肥胖妇女，口服补充氯化镁降低血浆ALT水平; hs-CRP水平只显示出下降趋势。
To evaluate the effect of oral supplementation with magnesium chloride on the systemic and hepatic inflammation, 38 non-hypertensive obese women aged 30 to 65 years were allocated into groups with and without hypomagnesemia. Hypomagnesemic women drank 50 mL of 5% solution of MgCl2 equivalent to 450 mg of elemental magnesium. Low-carbohydrate diets and physical activity were indicated for women in both groups. Chronic diarrhea, alcohol intake, use of diuretics, previous oral magnesium supplementation, hepatic disease, and renal damage were exclusion criteria. Hypomagnesemia is defined by serum magnesium concentrations = 40 U/L, and systemic inflammation by serum high-sensitivity C reactive protein (hs-CRP) concentration >= 3 mg/L. At baseline (p = 0.06) and final of follow-up (p = 0.80), there were no significant differences by body mass index between the groups in the study. In the same way, at baseline ALT (48.1 +/- 25.5 and 34.6 +/- 24.1 U/L, p = 0.14) and hs-CRP (9.4 +/- 6.0 and 7.9 +/- 5.9 mg/dL, p = 0.47) levels were similar in the supplemented and non-supplemented women. In the magnesium group, ALT (24.3 +/- 10.3 and 34.8 +/- 13.6 U/L, p = 0.02) levels, but not hs-CRP (5.2 +/- 1.9 and 8.0 +/- 5.6 mg/L, p = 0.08) reached significantly lower levels, in the fourth month of treatment, than in women in the control group. The adjusted odds ratios between the improvement in serum magnesium and reduction in ALT and hs-CRP levels were 0.56 (95% CI: 0.3-0.9) and 0.93 (95% CI: 0.6-29.9), respectively. Results of this study show that in hypomagnesemic obese women, oral supplementation with magnesium chloride reduces plasma ALT levels; hs-CRP levels only show a reduction trend.